Brought to you by 
Teva becomes European generics leader via ratiopharm takeover
29 Mar 2011
Executive Summary
Following several months of rumored offers from the likes of Pfizer and Actavis, Teva Pharmaceutical Industries has managed to sign a definitive agreement to acquire ratiopharm, a top private generic drug maker, for €3.625bn ($4.989bn), which includes the assumption of €600mm in debt. Ratiopharm is owned by VEM Holding, an asset management company controlled by the Merckle family.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- OTC, Consumer
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Teva becomes European generics leader via ratiopharm takeover
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice